Imunon Inc (NASDAQ:IMNN) announced positive results from their phase 2 Ovation 2 study, showing significant improvement in ...

Stacy Lindborg; Independent Director; Imunon Inc. Presentation. Operator. Good morning. My name is Mike, and I will be your operator today. At this time, I would lik ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...

Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...

Ended 2024 with $5.9M in cash and cash equivalents. The company believes it has sufficient capital resources to fund its operations into late ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

IMUNON’s TheraPlas is a non-viral delivery system that can support development of a range of immunotherapies and other anti-cancer nucleic acid-based therapies. For example, using this advanced ...

After hours: 7:29:47 p.m. EST ...

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant ...

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...